- Atezolizumab for Advanced Alveolar Soft Part Sarcoma🔍
- Atezolizumab approved for advanced alveolar soft part sarcoma🔍
- Atezolizumab Shrinks Alveolar Soft Part Sarcomas🔍
- Phase II study of atezolizumab in advanced alveolar soft part ...🔍
- FDA grants approval to atezolizumab for alveolar soft part sarcoma🔍
- Efficacy of immune checkpoint inhibitors in alveolar soft|part sarcoma🔍
- Atezolizumab as the First Systemic Therapy Approved for Alveolar ...🔍
- Atezolizumab induces durable responses in advanced alveolar soft ...🔍
Atezolizumab for Advanced Alveolar Soft Part Sarcoma
Atezolizumab for Advanced Alveolar Soft Part Sarcoma
Conclusions. Atezolizumab was effective at inducing sustained responses in approximately one third of patients with advanced ASPS. (Funded by ...
Atezolizumab for Advanced Alveolar Soft Part Sarcoma - PubMed
Atezolizumab was effective at inducing sustained responses in approximately one third of patients with advanced ASPS.
Atezolizumab approved for advanced alveolar soft part sarcoma - NCI
A clinical trial led by NCI has resulted in FDA approval of the immunotherapy drug atezolizumab (Tecentriq) to treat advanced alveolar soft ...
Atezolizumab Shrinks Alveolar Soft Part Sarcomas - NCI
Treatment with atezolizumab (Tecentriq) shrank tumors in nearly 40% of people with alveolar soft part sarcoma, according to new clinical ...
Phase II study of atezolizumab in advanced alveolar soft part ...
11519Background: ASPS constitutes < 1% of soft tissue sarcomas and frequently presents in adolescents and young adults.
A Robust, Durable Activity of Atezolizumab Observed in a Diverse
1 occurred in approximately one third (37%) of the patients with alveolar soft part sarcoma, many of whom had disease progression during ...
FDA grants approval to atezolizumab for alveolar soft part sarcoma
On December 9, 2022, the Food and Drug Administration (FDA) approved atezolizumab (Tecentriq, Genentech, Inc.) for adult and pediatric patients 2 years of ...
Phase II study of atezolizumab in advanced alveolar soft part ...
11519 Background: ASPS constitutes < 1% of soft tissue sarcomas and frequently presents in adolescents and young adults. There are no approved therapies for ...
Efficacy of immune checkpoint inhibitors in alveolar soft-part sarcoma
More recently, a phase II study assessed the efficacy of atezolizumab in a cohort of 49 patients with advanced ASPS, showing objective responses ...
Atezolizumab as the First Systemic Therapy Approved for Alveolar ...
... advanced setting, the approval of atezolizumab ... Atezolizumab as the First Systemic Therapy Approved for Alveolar Soft Part Sarcoma.
Atezolizumab induces durable responses in advanced alveolar soft ...
Atezolizumab induced durable responses among more than one-third of patients with advanced alveolar soft part sarcoma, according to data ...
Atezolizumab for advanced alveolar soft part sarcoma
Atezolizumab for advanced alveolar soft part sarcoma. Alice P Chen. National Cancer Institute. Brian A Van Tine. Washington University School of ...
PD-L1 Inhibition for Advanced Alveolar Soft-Part Sarcoma
The investigators concluded: “Atezolizumab was effective at inducing sustained responses in approximately one-third of patients with advanced ...
Atezolizumab Yields Durable Responses in Alveolar Soft Part ...
support the use of atezolizumab as a safe and effective treatment for advanced [alveolar soft part sarcoma],” the researchers wrote. “Further ...
Alveolar Soft Part Sarcoma (ASPS) Study Absract
Phase II Study of Atezolizumab in Advanced Alveolar Soft Part Sarcoma (ASPS). Abdul Rafeh Naqash1, Geraldine Helen O'Sullivan Coyne1, Nancy Moore1, Elad ...
Dr. Naqash and Dr. Chen on the Efficacy of Atezolizumab ... - OncLive
... atezolizumab in patients with advanced alveolar soft part sarcoma ... Chen on the Efficacy of Atezolizumab in Advanced Alveolar Soft Part Sarcoma.
First treatment approval for advanced ASPS
A Phase II trial has led to the FDA approval of atezolizumab for individuals over two years old with advanced alveolar soft part sarcoma.
Atezolizumab for advanced alveolar soft part sarcoma
BACKGROUND: Alveolar soft part sarcoma (ASPS) is a rare soft-tissue sarcoma with a poor prognosis and no established therapy.
Atezolizumab for Advanced Alveolar Soft Part Sarcoma
CONCLUSIONS. Atezolizumab was effective at inducing sustained responses in approximately one third of patients with advanced ASPS. (Funded by ...
Atezolizumab can induce response in alveolar soft part sarcoma
The immunotherapy agent atezolizumab induces sustained responses in about one-third of patients with advanced alveolar soft part sarcoma ...